PHIO (Phio Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of May. 04, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Forward Dividend Yield %?

As of today (2025-05-04), the Forward Annual Dividend Yield of Phio Pharmaceuticals is 0.00%.

As of today (2025-05-04), the Trailing Annual Dividend Yield of Phio Pharmaceuticals is 0.00%.

PHIO's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful Forward Dividend Yield % only.

Phio Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Phio Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Phio Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Phio Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Phio Pharmaceuticals (NAS:PHIO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Phio Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Apex Drive, Suite 300A PMB 2006, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581